-
Doctors Given Power to Vaccinate Young Children Without the Knowledge of Parents
-
Chris Hedges Speaks on ‘American Sadism’
-
The War on Reality
-
Subway’s tuna sandwiches found to contain no tuna fish DNA, lab tests find following lawsuit
-
What Price “Defense”?
-
Siberian Heat Wave Nearly Impossible Without Human Influence
A low Omega-3 index is just as strong a predictor of early death as smoking
Fatty Acid Research Institute (US), June 24, 2021
A new research paper published in the American Journal of Clinical Nutrition last week showed that a low Omega-3 Index is just as powerful in predicting early death as smoking. This landmark finding is rooted in data pulled and analyzed from the Framingham study, one of the longest running studies in the world.
The Framingham Heart Study provided unique insights into cardiovascular disease (CVD) risk factors and led to the development of the Framingham Risk Score based on eight baseline standard risk factors–age, sex, smoking, hypertension treatment, diabetes status, systolic blood pressure, total cholesterol (TC), and HDL cholesterol.
CVD is still the leading cause of death globally, and risk can be reduced by changing behavioral factors such as unhealthy diet, physical inactivity, and use of tobacco and alcohol. Therefore, researchers in this study say biomarkers integrating lifestyle choices might help identify individuals at risk and be useful to assess treatment approaches, prevent morbidity, and delay death.
Among the diet-based biomarkers are fatty acids (FAs), whether measured in plasma or red blood cell (RBC) membranes. The FAs most clearly associated with reduced risk for CVD and for total mortality (i.e., death from any cause) are the omega-3 FAs, EPA and DHA, which are typically found in fish like salmon and herring, as well as omega-3 supplements like fish and algal oil.
In a 2018 report that included 2500 participants in the Framingham Offspring Cohort followed for a median of 7.3 years (i.e., between ages ?66 and 73), the baseline RBC EPA + DHA content [the omega-3 index (O3I)] was significantly and inversely associated with risk for death from all causes.
In fact, individuals with the highest Omega-3 Index were 33% less likely to succumb during the follow-up years compared with those with the lowest Omega-3 Index. Similar associations have been seen in the Women’s Health Initiative Memory Study, the Heart and Soul Study, and the Ludwigshafen Risk and Cardiovascular Health Study.
The Omega-3 Index measures the amount of EPA and DHA in red blood cell membranes and is a marker of omega-3 status. An optimal Omega-3 Index is 8% or higher, an intermediate Omega-3 Index is between 4% and 8%, and a low Omega-3 Index is 4% and below. Most Americans have an Omega-3 Index below 4%, which puts them a significantly higher risk of early death.
According to researchers in this study, the finding that any FA-based metric would have predictive power similar to that of the well-established standard risk factors was unexpected, and it suggests that RBC FAs–via imperfectly understood mechanisms–somehow reflects an in vivo milieu that consolidates into one measure the impact on the body of all these standard risk factors.
“It is interesting to note that in Japan, where the mean Omega-3 Index is greater than 8%, the expected life span is around five years longer than it is in the United States, where the mean Omega-3 Index is about 5%. Hence, in practice, dietary choices that change the Omega-3 Index may prolong life,” said Michael McBurney, PhD, FCNS-SCN, lead researcher in this study. “In the final combined model, smoking and the Omega-3 Index seem to be the most easily modified risk factors. Being a current smoker (at age 65) is predicted to subtract more than four years of life (compared with not smoking), a life shortening equivalent to having a low vs. a high Omega-3 Index.”
“The information carried in the concentrations of four red blood cell fatty acids was as useful as that carried in lipid levels, blood pressure, smoking, and diabetic status with regard to predicting total mortality,” said Dr. Bill Harris, who was also an author on this study. “This speaks to the power of the Omega-3 Index as a risk factor and should be considered just as important as the other established risk factors, and maybe even more so.”
With age, insufficient tryptophan alters gut microbiota, increases inflammation
Medical College of Georgia , June 24, 2021
With age, a diet lacking in the essential amino acid tryptophan — which has a key role in our mood, energy level and immune response — makes the gut microbiome less protective and increases inflammation body-wide, investigators report.
In a normally reciprocal relationship that appears to go awry with age, sufficient tryptophan, which we consume in foods like milk, turkey, chicken and oats, helps keep our microbiota healthy.
A healthy microbiota in turn helps ensure that tryptophan mainly results in good things for us like producing the neurotransmitter serotonin, which reduces depression risk, and melatonin, which aids a good night’s sleep, says Dr. Sadanand Fulzele, an aging researcher in the Medical College of Georgia Department of Medicine.
But in aged mice, just eight weeks on a low-tryptophan diet results in some unhealthy changes in the trillions of bacteria that comprise the gut microbiota and higher levels of systemic inflammation, they report in the International Journal of Molecular Sciences.
Diet has been directly linked to microbiota composition in humans and rodents, they write, and they were able to document impactful shifts.
For example, when tryptophan levels are low, the MCG investigators found lower levels of Clostridium sp., the bacterium that metabolizes the essential amino acid enabling production of good products like serotonin in the gut, and a threefold increase in the bacterium Acetatifactor, which is associated with intestinal inflammation.
“We think the microbiome plays an important role in the aging process and we think one of those players in the aging is tryptophan, which produces metabolites that affect every organ function,” says Dr. Carlos M. Isales, co-director of the MCG Center for Healthy Aging and chief of the MCG Division of Endocrinology, Diabetes and Metabolism. “We also have evidence that the composition of the bacteria that utilize tryptophan changes so even if you eat more tryptophan, you may not use it correctly,” he says.
Fulzele and Isales are co-corresponding authors of the new study further exploring the relationship between tryptophan, the gut microbiome and the inflammatory response, in which they fed the aged mice three different diets for eight weeks — diets that were deficient, had recommended levels and high levels of tryptophan.
In the face of low tryptophan, they saw both a direct and indirect impact on the microbiota. These included changes like reduced levels of the bacterium Mucispirillum and Blautia, which play a big role in maintaining microbiota health in humans and animals. Some of these bacteria also have been found to be significantly decreased in patients with Crohn’s and colitis, where inflammation can be rampant. Mucispirillum, for example, resists oxidative “bursts” associated with inflammation and produces numerous factors associated with reducing reactive oxygen species and consequently inflammation.
It was the unhealthy changes they saw in the microbiota that made Fulzele, Isales and their colleagues also suspect increased release of inflammation-promoting signaling molecules called cytokines, hypothesizing that microbiota changes might induce release of the molecules body-wide. They looked specifically at the largely inflammation-promoting IL-17 and IL-1a as well as IL-6 and IL-27, which can both promote and suppress inflammation, in the blood of mice on a low tryptophan diet. They found significant increases of IL-6, IL-17A and IL-1a and a significant decrease in IL-27, a cytokine which prevents transcription of inflammation-invoking IL-17 and helps do things like increase regulatory T cells in the gut, which suppress inflammation. Conversely, mice on a tryptophan-rich diet had higher levels of the calming IL-27.
Generally the low-tryptophan diet set the stage for inflammation body-wide, the investigators say.
When the aged mice resumed a healthy tryptophan intake, some of the unhealthy changes resolved in just a few days, Fulzele notes. But the reality that just increasing tryptophan did not always correct problems, and that some tryptophan metabolites are actually harmful, provides more evidence that a better option is giving select metabolites early on to help keep the microbiota functioning optimally, rather than attempting a tryptophan rescue, the investigators say.
Their current work is further exploring what a good metabolite mix would look like. “We want to define what products that the gut generates that are good versus bad,” Isales says.
Each human has a unique microbiota that results from our birth mothers, and can change based on what we consume, breathe in or are otherwise exposed to over time. It is generally considered an organ system that enables us to digest food and has a key role in the immune response and our overall health. The microbiota also should help protect us from the ill effects of environmental exposures at all ages, and from the ravages of aging itself, Isales says.
Those ravages can include a reduced sense of smell, taste and appetite, and related dietary changes like inadequate or poor nutrition. Also, stem cells throughout the body, which are designed to keep us functioning at a premium by repairing or replacing dysfunctional cells, become less functional because of the cumulative effect of toxins we are exposed to. In a bit of a vicious cycle, our body systems become less efficient, most of us lose lean muscle mass and gain fat, which produces inflammatory molecules, and our weight shifts around so we store more of that fat in and around our abdominal area where it tends to be the most inflammatory and lethal. Fat is also less efficient than lean muscle at burning calories so our metabolism slows, which should in theory slow aging, but in the face of other changes mostly cannot.
“Basically your immune system has been dysregulated, you have continued inflammation from damaged tissue by the processes that normally keep you healthy,” Isales says as chronic inflammation can replace the classic episodic immune response that fights infection and enables healing.
What Isales calls this “unnatural” process of aging, is associated with chronic disease conditions like impaired digestive health, declining cognitive function and a compromised immune system, and he and Fulzele agree that the gut microbiota is a significant modulator of these.
“We accept as normal that your organs stop working as well. We accept that the ejection fraction of your heart drops as you get older. We accept that your brain function decreases as you get older. We accept as normal what is not normal,” says Isales, who along with Fulzele and their other colleagues in the MCG Center for Healthy Aging want to help reestablish for most of us what they consider the ability to live a significantly longer, and healthier life.
Amino acids like tryptophan are the building blocks for protein production, and proteins are the product our cells produce, which determine their function and ultimately the function of our organs and tissues.
Broccoli Pill Could Be Next Big Autism Treatment
University of California San Francisco, June 29, 2021
Parents of children with autism constantly search for new methods of treatment to cure or, at the very least, alleviate the symptoms of their child’s illness. For the most part, the damage has been done when it comes to the effects on the brain and, for that reason, many parents find themselves on goose chase after goose chase.
While mainstream media, Big Pharma, and the medical industry refuse to look at the cause of autism, however, there is research being done in regards to the symptoms.
One such study, “Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli.,” published in Molecular Autism has taken a look at using “urinary metabolomics analysis” as a method of identifying pathways that might be involved in the treatment of abnormal physiology in ASD (Autism Spectrum Disorder).
Basically, it has been discovered that children with autism have “urinary metabolites” which suggest impairments in a number of pathways, – oxidative stress, mitochondrial dysfunction, inflammation, and gut microbiome alterations.
Interestingly enough, sulforaphane, a supplement with indirect antioxidant effects, has been shown to lead to improvements in the social responsiveness and behavior of children with ASD.
The study was designed to look at changes in urinary metabolites associated with clinical improvements in order to determine a “potential mechanism of action,” i.e. how it works.
Notably, sulforaphane is derived from broccoli sprouts and seeds.
Not only broccoli and broccoli seeds but Brussel sprouts and cabbage are also high in sulforaphane.
While certainly not a cure for autism, such research does provide hope for parents who are struggling to relieve the symptoms of their children’s illness.
Western high-fat diet can cause chronic pain, according to research team
University of Texas Health Science Center, June 24, 2021
A typical Western high-fat diet can increase the risk of painful disorders common in people with conditions such as diabetes or obesity, according to a groundbreaking paper authored by a team led by The University of Texas Health Science Center at San Antonio, also referred to as UT Health San Antonio.
Moreover, changes in diet may significantly reduce or even reverse pain from conditions causing either inflammatory pain—such as arthritis, trauma or surgery—or neuropathic pain, such as diabetes. The novel finding could help treat chronic-pain patients by simply altering diet or developing drugs that block release of certain fatty acids in the body.
The paper, more than five years in the making, was published in the June edition of the journal Nature Metabolism by a collaborative team of 15 local researchers, headed by first co-authors Jacob T. Boyd, MD, Ph.D., and Peter M. LoCoco, Ph.D., of the Department of Endodontics at UT Health San Antonio.
In all, 11 of the co-authors are from UT Health San Antonio, including seven current or former students of its Graduate School of Biomedical Sciences; three represent the Department of Chemistry at the University of Texas at San Antonio; and one is from the Department of Neurology with the South Texas Veterans Health Care System.
“This study exemplifies team science at its best—multiple scientists and clinicians with complementary expertise working together to make lives better,” said Kenneth M. Hargreaves, DDS, Ph.D., professor and chair of the Department of Endodontics at UT Health San Antonio, and senior author of the paper.
Fatty acids and pain
Chronic pain is a major cause of disability around the world. But although fat-reduction often is advised to manage diabetes, auto-immune disorders and cardiovascular diseases, the role of dietary lipids, or fatty acids, in pain conditions has been relatively unknown.
In the new paper, Dr. Boyd and his colleagues used multiple methods in both mice and humans to study the role of polyunsaturated fatty acids in pain conditions. They found that typical Western diets high in omega-6 polyunsaturated fats served as a significant risk factor for both inflammatory and neuropathic pain.
Omega-6 fats, mainly found in foods with vegetable oils, have their benefits. But Western diets associated with obesity are characterized by much-higher levels of those acids in foods from corn chips to onion rings, than healthy omega-3 fats, which are found in fish and sources like flaxseed and walnuts.
Generally, unhealthy foods high in omega-6 fats include processed snacks, fast foods, cakes, and fatty and cured meats, among others.
Reversal of this diet, especially by lowering omega-6 and increasing omega-3 lipids, greatly reduced these pain conditions, the researchers found. Also, the authors demonstrated that skin levels of omega-6 lipids in patients with Type 2 diabetic neuropathic pain were strongly associated with reported pain levels and the need for taking analgesic drugs.
“This paper is a high-profile contribution for a huge unmet translational need as there are no treatments altering the nature of this neurological disease,” said José E. Cavazos, MD, Ph.D., professor of neurology, assistant dean and director of the National Institutes of Health-designated South Texas Medical Scientist Training Program at UT Health San Antonio.
In an editorial accompanying the paper, Duke University researchers Aidan McGinnis and Ru-Rong Ji wrote, “This comprehensive and elegant study from Boyd et al. may serve as a foundation for new clinical trials and ultimately provide new avenues for the clinical treatment of neuropathies.”
Could coconut oil help Alzheimer disease patients?
Central Plantation Crops Research Institute (India), June 25, 2021
According to news reporting originating in Kerala, India,research stated, “Alzheimer’s disease (AD) is a devastating neurodegenerative ailment having pathological hallmarks of plaques due to amyloid beta (A beta) peptides and neurofibrillary tangles in brain. These cerebral plaques and neurofibrillary tangles potentially affect the neuronal synaptic transmission and ultimately cause cognitive decline.”
The news reporters obtained a quote from the research from the Indian Council of Agricultural Research (ICAR) Central Plantation Crops Research Institute, “In the absence of an effective treatment module for AD, alternative therapeutic strategies are being explored. Scope and approach: Given the fact that dysregulation of brain glucose metabolism is an early detectable trait of AD, coconut oil and its variants/derivatives have generated considerable interests as an invaluable therapeutic agent for AD. The role of coconut oil-derived medium chain fatty acids (MCFAs) which are rapidly metabolized into ketone bodies to serve as an alternate source of energy for the cerebral tissue is well recognized. Recently, evidences underlying the mode of action of coconut oil in alleviating the symptoms of AD have started emerging. In this review, a comprehensive snapshot of the recent developments and biochemical basis of coconut oilinduced amelioration of AD symptoms including its dietary role in suppression of neuro-inflammation, reversing the process of neurodegeneration, enhancement of cell survival pathways and inhibition of secretion of A beta peptides are presented. Investigations in animal models and clinical trials in humans using coconut oil and its derivatives aimed at reversing the AD-induced cognitive decline are also discussed. To conclude the knowledge gaps in the treatment of AD using coconut oil and way forward are presented. Key findings and conclusion: Scientific evidences point toward the immense therapeutic value of coconut oil in the prevention or treatment of AD through its multi-pronged biochemical effects.”
According to the news reporters, the research concluded: “Nevertheless, identification of bioactive components, besides MCFAs, responsible for the neuroprotective effects, clinical trials to fix the dosage and consolidation of information flow are warranted.”
This research has been peer-reviewed.
Study shows potential dangers of sweeteners
New research: Sweeteners could cause gut bacteria to invade the intestine
Anglia Ruskin University, June 25, 2021
New research has discovered that common artificial sweeteners can cause previously healthy gut bacteria to become diseased and invade the gut wall, potentially leading to serious health issues.
The study, published in the International Journal of Molecular Sciences, is the first to show the pathogenic effects of some of the most widely used artificial sweeteners – saccharin, sucralose, and aspartame – on two types of gut bacteria, E. coli (Escherichia coli) and E. faecalis (Enterococcus faecalis).
Previous studies have shown that artificial sweeteners can change the number and type of bacteria in the gut, but this new molecular research, led by academics from Anglia Ruskin University (ARU), has demonstrated that sweeteners can also make the bacteria pathogenic. It found that these pathogenic bacteria can attach themselves to, invade, and kill Caco-2 cells, which are epithelial cells that line the wall of the intestine.
It is known that bacteria such as E. faecalis which cross the intestinal wall can enter the blood stream and congregate in the lymph nodes, liver, and spleen, causing a number of infections including septicaemia.
This new study discovered that at a concentration equivalent to two cans of diet soft drink, all three artificial sweeteners significantly increased the adhesion of both E. coli and E. faecalis to intestinal Caco-2 cells, and differentially increased the formation of biofilms.
Bacteria growing in biofilms are less sensitive to antimicrobial resistance treatment and are more likely to secrete toxins and express virulence factors, which are molecules that can cause disease.
Additionally, all three sweeteners caused the pathogenic gut bacteria to invade Caco-2 cells found in the wall of the intestine, with the exception of saccharin which had no significant effect on E. coli invasion.
Senior author of the paper Dr Havovi Chichger, Senior Lecturer in Biomedical Science at Anglia Ruskin University (ARU), said: “There is a lot of concern about the consumption of artificial sweeteners, with some studies showing that sweeteners can affect the layer of bacteria which support the gut, known as the gut microbiota.
“Our study is the first to show that some of the sweeteners most commonly found in food and drink – saccharin, sucralose and aspartame – can make normal and ‘healthy’ gut bacteria become pathogenic. These pathogenic changes include greater formation of biofilms and increased adhesion and invasion of bacteria into human gut cells.
“These changes could lead to our own gut bacteria invading and causing damage to our intestine, which can be linked to infection, sepsis and multiple-organ failure.
“We know that overconsumption of sugar is a major factor in the development of conditions such as obesity and diabetes. Therefore, it is important that we increase our knowledge of sweeteners versus sugars in the diet to better understand the impact on our health.”
Substance found in grapes prevents agglomeration of a mutant protein that leads to cancer
Brazilian study shows the action of resveratrol on the inhibition of amyloid aggregates of mutant p53 protein, a mutation found in more than half of malignant tumors
Federal University of Rio de Janeiro & State University of Rio de Janeiro, June 29, 2021
Researchers at the Federal University of Rio de Janeiro (UFRJ) and the State University of Rio de Janeiro (UERJ) have made a discovery that may lead to the development of a treatment capable of acting against more than half the cases of breast cancer. Using resveratrol, a bioactive compound found in grapes and red wine, scientists were able for the first time to inhibit the agglomeration of mutant versions of the p53 protein, a structure present in about 60% of tumors, and to prevent migration and proliferation of breast cancer cells.
The potential anti-cancer effects of resveratrol have been known for years, but to date no study has been able to show that the substance can act to reduce tumors caused by the aggregation of the mutant form of tumor suppressor p53. The Brazilians are the first to obtain this result in the laboratory.
Because they are found in more than half of malignant tumors, amyloid aggregates of mutant p53 are considered novel strategic targets in the fight against cancer. In its normal, unmutated version, the protein is responsible for the suppression of tumor cells, and for this reason is often referred to as “guardian of the genome”. A mutant p53, however, can lose that function and gain others, sequestering its normal counterparts and contributing to the formation of amyloid aggregates, structures of difficult degradation and rapid growth. Some p53 mutations are extremely pathogenic, while others are harmless.
The laboratory of Jerson Lima Silva, professor of the Institute of Medical Biochemistry Leopoldo de Meis (IBqM) and the National Center for Structural Biology and Bioimaging (CENABIO) of UFRJ and coordinator of the National Institute of Science and Technology of the same name (INBEB), has been investigating the amyloid aggregation of p53 for two decades. The main goal of this group is to understand the mechanisms that allow aggregates of mutant p53 to contribute to cancer and to find an effective way to prevent it from forming.
“The findings bring scientists closer to the development of a drug capable of acting directly on the amyloid aggregation of the mutant p53”, states Danielly C. Ferraz da Costa, a co-author of the study, from the Institute of Nutrition of UERJ and a member of the INBEB. She began studying the properties of resveratrol for her doctoral thesis, and by 2012 had already investigated the anticancer protection by resveratrol in lung tumor cells.
The researchers applied fluorescence spectroscopy techniques in vitro to test the antitumor potential of resveratrol in aggregations of wild and mutant p53. In addition, they used immunofluorescence co-localization assays to test the action of the substance on breast cancer cells with different p53 mutants (MDA-MB-231 and HCC-70) and normal p53 (MCF-7). Decreased aggregation of mutated p53 was observed in tumors implanted in mice. The group is now studying various molecules derived from resveratrol that can be used in therapy against tumors containing mutated p53.
